Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Bought by Teacher Retirement System of Texas

Teacher Retirement System of Texas grew its position in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 18.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,415 shares of the company’s stock after acquiring an additional 2,274 shares during the period. Teacher Retirement System of Texas’ holdings in Akero Therapeutics were worth $401,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Wellington Management Group LLP raised its holdings in Akero Therapeutics by 54.4% in the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after purchasing an additional 2,782,029 shares during the period. Janus Henderson Group PLC raised its stake in shares of Akero Therapeutics by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock worth $203,053,000 after buying an additional 201,225 shares during the period. RTW Investments LP lifted its position in shares of Akero Therapeutics by 9.0% during the 3rd quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock valued at $169,829,000 after buying an additional 487,450 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Akero Therapeutics during the 3rd quarter valued at approximately $37,392,000. Finally, SG Americas Securities LLC increased its holdings in Akero Therapeutics by 4,022.1% in the 4th quarter. SG Americas Securities LLC now owns 597,993 shares of the company’s stock worth $16,636,000 after acquiring an additional 583,486 shares in the last quarter.

Analyst Ratings Changes

Several research firms have issued reports on AKRO. Morgan Stanley reaffirmed an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. HC Wainwright lifted their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $35.00 to $63.00 in a report on Thursday, January 30th. UBS Group lifted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Finally, Citigroup increased their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $76.29.

Insider Buying and Selling at Akero Therapeutics

In other news, VP Patrick Lamy sold 5,000 shares of Akero Therapeutics stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $57.03, for a total transaction of $285,150.00. Following the sale, the vice president now owns 33,492 shares of the company’s stock, valued at approximately $1,910,048.76. The trade was a 12.99 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Cheng sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $54.90, for a total value of $1,647,000.00. Following the completion of the transaction, the chief executive officer now owns 716,062 shares in the company, valued at $39,311,803.80. This represents a 4.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 341,309 shares of company stock worth $15,863,578 and have sold 252,135 shares worth $12,345,079. 7.94% of the stock is currently owned by company insiders.

Akero Therapeutics Stock Performance

Shares of Akero Therapeutics stock opened at $40.48 on Tuesday. The business’s 50 day moving average price is $46.32 and its 200 day moving average price is $35.25. The company has a market cap of $3.22 billion, a price-to-earnings ratio of -10.79 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a one year low of $17.86 and a one year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). On average, research analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.